| Literature DB >> 33014327 |
M A Sánchez1, J E Segura1, G Alajmo1, J M Nossa1, A Correa1, E Leal1, A Moscoso1, G A Pineda1, A C Aya1.
Abstract
PURPOSE: To describe the implementation of a postfracture care program in a private hospital in Colombia, the results achieved after the program's first year, and the challenges encountered.Entities:
Year: 2020 PMID: 33014327 PMCID: PMC7519994 DOI: 10.1155/2020/8208397
Source DB: PubMed Journal: J Osteoporos ISSN: 2042-0064
ICD 10 codes used for the diagnosis of fragility fractures.
| Diagnosis | ICD10 code |
|---|---|
| Fracture of thoracic vertebra | S220 |
| Fracture of femur, part unspecified | S729 |
| Fracture of lower end of radius | S525 |
| Fracture of upper end of humerus | S422 |
| Unspecified spine fracture | T08X |
Figure 1Postfracture care program and study flowchart. aWorkup included laboratory testing and dual X-ray absorptiometry (DXA).
Patients' comorbidities and fall risk factors.
| Type of disease |
|
|---|---|
|
| |
| Hypertension | 104 (54.7) |
| Type 2 diabetes | 22 (11.6) |
| Rheumatoid arthritis | 7 (3.7) |
|
| |
|
| |
| Antidepressants | 18 (9.5) |
| Alcohol | 2 (1.1) |
| Corticosteroids | 6 (3.2) |
| Smoking | 10 (5.3) |
|
| |
|
| |
| Neurological disordera | 15 (7.9) |
| COPD | 21 (11.1) |
| Hypothyroidism | 43 (22.6) |
COPD: chronic obstructive pulmonary disease. Data are expressed as numbers (percentage). aAlzheimer's disease, Parkinson's disease, or dementia.
Figure 2Previous and current fragility fracture sites. Data are expressed as numbers (percentage). aBefore the program; bduring the study period (year 1 of the program).
Figure 3Assessment and care of fragility fracture patients during the study period. aTwenty-three percent of patients (n = 44) were not evaluated since they already had a diagnosis of osteoporosis. bLaboratory testing included serum albumin, complete blood count, serum creatinine, vitamin D levels, total calcium, alkaline phosphatase, and parathormone and DXA dual-energy X-ray absorptiometry.
Postfracture treatment outcomes.
| Outcomes |
|
|---|---|
|
| |
| Medical | 83 (43.7) |
| Surgical | 107 (56.3) |
| Radius osteosynthesis | 37 (19.5) |
| Hip osteosynthesis | 35 (18.4) |
| Total hip replacement | 23 (12.1) |
| Total shoulder replacement | 4 (2.1) |
| Humerus osteosynthesis | 3 (1.6) |
| Partial hip replacement | 3 (1.6) |
| Vertebroplasty | 2 (1) |
|
| |
|
| |
| Less than 48 h | 94 (87.8) |
| 48 h or more | 13 (12.1) |
|
| |
|
| |
| Hospitalization | 4.7 ± 4.3 |
| Intensive care unit | 2.7 ± 1.4 |
|
| |
|
| |
| No | 117 (61.6) |
| Yes | 73 (39.4) |
| Denosumab | 31 (16.3) |
| Teriparatide | 29 (15.3) |
| Zoledronic acid | 5 (2.6) |
| Alendronate | 5 (2.6) |
| Ibandronate | 3 (1.6) |
|
| |
|
| |
| Yes | 120 (63.1) |
| No | 70 (36.8) |
Data are expressed as numbers (percentage) or mean ± standard deviation (SD).a Calcium and vitamin D supplements.
Complications and morbidity outcomes during the first year of the program.
| Outcomes |
|
|---|---|
| Nosocomial complications | 4 (2) |
| Readmission within 30 days | 23 (12) |
| Reintervention | 2 (1) |
| Refracture | 2 (1) |
| Falls after hospital discharge | 11 (5.8) |
|
| |
|
| |
| During hospitalization | 2 (1) |
| Early (<30 days) | 2 (1) |
| Late (>30 days) | 2 (1) |
Data are expressed as numbers (percentage).